Kingswood Wealth Advisors LLC Invests $40,000 in Altimmune, Inc. $ALT

Kingswood Wealth Advisors LLC acquired a new position in Altimmune, Inc. (NASDAQ:ALT) during the second quarter, Holdings Channel reports. The institutional investor acquired 10,400 shares of the company’s stock, valued at approximately $40,000.

A number of other institutional investors have also made changes to their positions in ALT. Nuveen LLC bought a new position in shares of Altimmune in the first quarter worth about $1,304,000. Federated Hermes Inc. bought a new position in shares of Altimmune in the first quarter worth about $939,000. Hsbc Holdings PLC bought a new position in shares of Altimmune in the first quarter worth about $349,000. Brown Wealth Management LLC increased its stake in Altimmune by 100.0% during the first quarter. Brown Wealth Management LLC now owns 100,024 shares of the company’s stock valued at $500,000 after acquiring an additional 50,024 shares during the period. Finally, Baader Bank Aktiengesellschaft bought a new position in Altimmune during the second quarter valued at about $133,000. 78.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ALT has been the topic of several research reports. Wall Street Zen upgraded Altimmune from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. The Goldman Sachs Group upgraded Altimmune to a “strong sell” rating in a research note on Thursday, July 10th. William Blair restated a “market perform” rating on shares of Altimmune in a research note on Friday, June 27th. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Friday. Finally, JMP Securities lowered their price target on Altimmune from $25.00 to $15.00 and set a “market outperform” rating on the stock in a research note on Thursday, July 10th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $17.40.

Altimmune Stock Down 2.0%

NASDAQ ALT opened at $3.92 on Monday. The company has a current ratio of 20.44, a quick ratio of 20.44 and a debt-to-equity ratio of 0.09. The stock’s 50 day moving average is $3.72 and its two-hundred day moving average is $4.60. The company has a market capitalization of $345.98 million, a price-to-earnings ratio of -3.32 and a beta of 0.07. Altimmune, Inc. has a 1-year low of $2.90 and a 1-year high of $11.16.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.05. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%. Equities analysts forecast that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.